ProCE Banner Activity

TROPHY-U-01 Cohort 2: Sacituzumab Govitecan After Checkpoint Inhibition in Platinum-Ineligible Metastatic Urothelial Cancer

Capsule Summary
Conference Coverage
Slideset

Sacituzumab govitecan showed encouraging antitumor efficacy in platinum-ineligible patients with mUC with progression following ICI therapy.

Released: February 22, 2023

Expiration: February 21, 2024

No longer available for credit.

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.